share_log

Bluebird Bio Has Entered Into An Agreement To Sell A Rare Pediatric Disease Priority Review Voucher (PRV), If Received, In Connection With The Potential Approval Of Lovotibeglogene Autotemcel (Lovo-cel) For Sickle Cell Disease

Moomoo 24/7 ·  Oct 30, 2023 08:19

Under the terms of the agreement, rights to the PRV will transfer to the buyer and the Company will receive $103 million upon closing of the sale, which is contingent upon the FDA's approval of the biologics license application (BLA) for lovo-cel and granting of the PRV.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment